8-K: Mersana Therapeutics Announces Positive Initial Clinical Data and Additional FDA Fast Track Designation for Emiltatug Ledadotin

Mersana Therapeutics reports positive initial Phase 1 clinical trial data for Emiltatug Ledadotin (Emi-Le) and receives an additional FDA Fast Track designation for the treatment of advanced breast cancer.

Summary

• Mersana Therapeutics announced positive initial clinical data from its Phase 1 trial of Emiltatug Ledadotin (Emi-Le), an antibody-drug conjugate (ADC) targeting B7-H4.
• The trial enrolled 130 patients with various advanced cancers, including triple-negative breast cancer (TNBC), hormone-receptor positive breast cancer, ovarian cancer, endometrial cancer, and adenoid cystic carcinoma.
• Patients were heavily pretreated, with a median of 4.5 prior lines of therapy and 92% of TNBC patients having received at least one prior topoisomerase-1 inhibitor (topo-1) ADC.
• Approximately 44% of patients with known B7-H4 tumor expression had a tumor proportion score of 70% or higher, characterized as B7-H4 High.
• Emi-Le was generally well-tolerated, with the most common adverse events being transient AST increase (38%), proteinuria (31%), nausea (29%), and fatigue (28%).
• In the intermediate dose range (38.1 to 67.4 mg/m2), the confirmed objective response rate (ORR) was 23% in B7-H4 High tumors and 23% in B7-H4 High TNBC, all of whom had prior topo-1 ADC treatment.
• The company has initiated a dose expansion cohort at 67.4 mg/m2 every four weeks (Q4W) in post-topo-1 TNBC patients.
• An additional FDA Fast Track designation was granted for Emi-Le for the treatment of advanced or metastatic breast cancer in patients with HER2-low or HER2-negative disease, including TNBC, who have received a prior topo-1 ADC.
• Mersana expects its current capital resources to support its operating plan into 2026, with $155.2 million in cash, cash equivalents, and marketable securities as of September 30, 2024.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the promising clinical data, additional FDA Fast Track designation, and the company's financial stability. However, there are some concerns about side effects and dose delays.

Positives

• Emi-Le demonstrated promising clinical activity in heavily pretreated patients, particularly those with TNBC who had prior topo-1 ADC treatment.
• The safety profile of Emi-Le appears favorable, with no Grade 4 or 5 TRAEs reported and manageable side effects.
• The additional FDA Fast Track designation could expedite the development and review process for Emi-Le.
• The company has a clear plan for continued clinical development, including dose expansion and further data presentations.
• Mersana's financial position is stable, with sufficient capital to support operations into 2026.

Negatives

• Some patients experienced Grade 3 treatment-related adverse events, including AST increase (14%) and proteinuria (9%).
• Dose delays were required for some patients due to proteinuria, which the company is working to mitigate.
• Objective responses in the high dose range were not confirmed after protocol-mandated dose delays for proteinuria.

Risks

• The clinical development of Emi-Le and XMT-2056 is subject to uncertainties inherent in research and development.
• There is a risk of delays in patient enrollment for clinical trials.
• Outcomes of preclinical studies may not be predictive of clinical trial results.
• Initial or interim results from clinical trials may not be predictive of final results.
• Clinical trial data may not support regulatory applications or approvals.
• The company may not realize the intended benefits of its platforms, technology, and collaborations.
• The company's cash runway estimates may be inaccurate, or the business may require more cash than anticipated.

Future Outlook

Mersana plans to continue enrollment in the expansion cohort of the Emi-Le trial, initiate enrollment at a second dose, and present additional clinical data in 2025. They also plan to present initial clinical pharmacodynamic STING activation data for XMT-2056 in 2025.

Management Comments

• Martin Huber, M.D., President and Chief Executive Officer of Mersana Therapeutics, stated that the initial safety, tolerability, and efficacy data for Emi-Le demonstrate a profile that is exciting and differentiated within both the B7-H4 field and the broader ADC landscape.
• Martin Huber also noted that the growing population of patients who have received prior topo-1 ADCs is a primary focus for the company as they advance the development of Emi-Le.
• Erika Hamilton, M.D., Director Breast Cancer Research, Sarah Cannon Research Institute, commented that the Emi-Le data are encouraging in terms of both tolerability and clinical activity, and that it is notable that all the TNBC patients who responded to Emi-Le had previously been treated with at least one topo-1 ADC.

Industry Context

The announcement is significant as it addresses the unmet need for effective treatments in patients with advanced breast cancer, particularly those with TNBC who have progressed after treatment with topo-1 ADCs. The positive data and Fast Track designation position Mersana as a potential leader in the development of next-generation ADCs.

Comparison to Industry Standards

• The objective response rate (ORR) of 23% observed in the intermediate dose range of the Emi-Le trial is significantly higher than the approximately 5% ORR seen with standard-of-care single-agent chemotherapy in relapsed/refractory TNBC, as reported in the ASCENT Phase 3 clinical trial of sacituzumab govitecan.
• The progression-free survival (PFS) of approximately seven weeks with standard-of-care chemotherapy in the ASCENT trial highlights the need for more effective treatments, which Emi-Le aims to address.
• The differentiated safety profile of Emi-Le, with no dose-limiting treatment-related neutropenia, neuropathy, ocular toxicity, interstitial lung disease, or thrombocytopenia, is a notable advantage compared to some other approved and clinical-stage ADCs.

Stakeholder Impact

• Shareholders: The positive clinical data and Fast Track designation are likely to be viewed favorably by investors.
• Patients: The development of Emi-Le offers hope for a new treatment option for patients with advanced breast cancer, particularly those with TNBC.
• Employees: The progress of the clinical trials and the company's financial stability are positive for employee morale and job security.
• Partners: The continued collaborations with Johnson & Johnson and Merck KGaA are supported by the positive data.

Next Steps

• Continue enrollment in the expansion cohort at 67.4 mg/m2 Q4W in post-topo-1 TNBC patients.
• Initiate enrollment in expansion at a second dose in post-topo-1 TNBC patients.
• Present additional Phase 1 clinical data from dose escalation and backfill cohorts.
• Present initial clinical pharmacodynamic STING activation data for XMT-2056.

Key Dates

Keywords

Emiltatug Ledadotin, XMT-1660, Antibody-Drug Conjugate, ADC, B7-H4, Triple-Negative Breast Cancer, TNBC, Fast Track Designation, Oncology, Cancer Therapy